Altimmune, Inc.
ALT
$2.91
-$0.02-0.68%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 420.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | 420.00% | |||
| Cost of Revenue | -12.04% | 23.05% | |||
| Gross Profit | 11.92% | -22.92% | |||
| SG&A Expenses | -23.39% | 78.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.17% | 38.61% | |||
| Operating Income | 16.09% | -38.52% | |||
| Income Before Tax | 17.53% | -43.88% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 17.53% | -43.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.53% | -43.88% | |||
| EBIT | 16.09% | -38.52% | |||
| EBITDA | 16.09% | -38.57% | |||
| EPS Basic | 33.32% | -27.89% | |||
| Normalized Basic EPS | 33.31% | -27.84% | |||
| EPS Diluted | 33.32% | -27.89% | |||
| Normalized Diluted EPS | 33.31% | -27.84% | |||
| Average Basic Shares Outstanding | 23.70% | 12.52% | |||
| Average Diluted Shares Outstanding | 23.70% | 12.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||